Novartis cancels $1B sale of generics after antitrust concerns forced delays
Novartis has scrapped a generics sale that could have netted $1 billion after failing to obtain approval from the Federal Trade Commission on time. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
